These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 21109688)
21. Gene Modified T Cell Therapies for Hematological Malignancies. Abramowski-Mock U; Delhove JM; Qasim W Hematol Oncol Clin North Am; 2017 Oct; 31(5):913-926. PubMed ID: 28895856 [TBL] [Abstract][Full Text] [Related]
22. Adoptive therapy with CAR redirected T cells for hematological malignancies. Li S; Yang Z; Shen J; Shan J; Qian C Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302 [TBL] [Abstract][Full Text] [Related]
24. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation. Zilberberg J; Feinman R; Korngold R Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643 [TBL] [Abstract][Full Text] [Related]
25. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608 [TBL] [Abstract][Full Text] [Related]
27. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525 [TBL] [Abstract][Full Text] [Related]
28. Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs. Bijen HM; van der Steen DM; Hagedoorn RS; Wouters AK; Wooldridge L; Falkenburg JHF; Heemskerk MHM Mol Ther; 2018 May; 26(5):1206-1214. PubMed ID: 29567312 [TBL] [Abstract][Full Text] [Related]
29. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy. Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318 [TBL] [Abstract][Full Text] [Related]
30. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy. Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878 [TBL] [Abstract][Full Text] [Related]
31. Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells. van Loenen MM; de Boer R; Hagedoorn RS; Jankipersadsing V; Amir AL; Falkenburg JH; Heemskerk MH Gene Ther; 2013 Aug; 20(8):861-7. PubMed ID: 23364317 [TBL] [Abstract][Full Text] [Related]
32. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies. Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322 [TBL] [Abstract][Full Text] [Related]
33. Gammaretroviral Production and T Cell Transduction to Genetically Retarget Primary T Cells Against Cancer. Li G; Park K; Davila ML Methods Mol Biol; 2017; 1514():111-118. PubMed ID: 27787796 [TBL] [Abstract][Full Text] [Related]
34. T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production. Schaft N; Lankiewicz B; Drexhage J; Berrevoets C; Moss DJ; Levitsky V; Bonneville M; Lee SP; McMichael AJ; Gratama JW; Bolhuis RL; Willemsen R; Debets R Int Immunol; 2006 Apr; 18(4):591-601. PubMed ID: 16507598 [TBL] [Abstract][Full Text] [Related]